PMID- 36552050
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230308
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 10
IP  - 12
DP  - 2022 Dec 19
TI  - New Insights into the Use of Empagliflozin-A Comprehensive Review.
LID - 10.3390/biomedicines10123294 [doi]
LID - 3294
AB  - Empagliflozin is a relatively new drug that, as an inhibitor of the 
      sodium-glucose cotransporter 2 (SGLT2), causes increased urinary glucose 
      excretion and thus contributes to improved glycemic control, better glucose 
      metabolism, reduced glucotoxicity and insulin resistance. Although its original 
      use was to induce a hypoglycemic effect in patients with type 2 diabetes mellitus 
      (T2DM), empagliflozin has also shown a number of other beneficial effects by 
      demonstrating a nephroprotective effect, and it has proven to be a breakthrough 
      in the treatment of heart failure (HF). Empagliflozin has been shown to reduce 
      hospitalizations for HF and the number of deaths from cardiovascular causes. 
      Empagliflozin treatment also reduces the incidence of renal events, including 
      death from renal causes, as well as the risk of end-stage renal failure. 
      Empagliflozin appears to be a fairly well-tolerated and safe drug. In patients 
      with inadequate glycemic control, empagliflozin used in monotherapy or as an 
      adjunct to therapy effectively lowers fasting blood glucose, postprandial blood 
      glucose, average daily glucose levels, glycated hemoglobin A1C (HbA1C) and also 
      leads to significant weight reduction in patients with T2DM. Unfortunately, there 
      are some limitations, e.g., severe hypersensitivity reaction to the drug and a 
      glomerular filtration rate (GFR) < 30 mL/min/1.73 m2. As with any drug, 
      empagliflozin is also characterized by several side effects among which 
      symptomatic hypotension, troublesome genital fungal infections, urinary tract 
      infections and rare ketoacidosis are characteristic.
FAU - Forycka, Joanna
AU  - Forycka J
AUID- ORCID: 0000-0003-0154-6278
AD  - Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 
      90-549 Lodz, Poland.
FAU - Hajdys, Joanna
AU  - Hajdys J
AD  - Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 
      90-549 Lodz, Poland.
FAU - Krzeminska, Julia
AU  - Krzeminska J
AUID- ORCID: 0000-0003-4463-2731
AD  - Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 
      90-549 Lodz, Poland.
FAU - Wilczopolski, Piotr
AU  - Wilczopolski P
AD  - Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 
      90-549 Lodz, Poland.
FAU - Wronka, Magdalena
AU  - Wronka M
AD  - Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 
      90-549 Lodz, Poland.
FAU - Mlynarska, Ewelina
AU  - Mlynarska E
AUID- ORCID: 0000-0002-6799-4746
AD  - Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 
      90-549 Lodz, Poland.
FAU - Rysz, Jacek
AU  - Rysz J
AD  - Department of Nephrology, Hypertension and Family Medicine, Medical University of 
      Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland.
FAU - Franczyk, Beata
AU  - Franczyk B
AD  - Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 
      90-549 Lodz, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221219
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC9775057
OTO - NOTNLM
OT  - chronic kidney disease (CKD)
OT  - empagliflozin
OT  - heart failure (HF)
OT  - type 2 diabetes mellitus (T2DM)
COIS- The authors declare no conflict of interest.
EDAT- 2022/12/24 06:00
MHDA- 2022/12/24 06:01
PMCR- 2022/12/19
CRDT- 2022/12/23 01:13
PHST- 2022/11/14 00:00 [received]
PHST- 2022/12/12 00:00 [revised]
PHST- 2022/12/13 00:00 [accepted]
PHST- 2022/12/23 01:13 [entrez]
PHST- 2022/12/24 06:00 [pubmed]
PHST- 2022/12/24 06:01 [medline]
PHST- 2022/12/19 00:00 [pmc-release]
AID - biomedicines10123294 [pii]
AID - biomedicines-10-03294 [pii]
AID - 10.3390/biomedicines10123294 [doi]
PST - epublish
SO  - Biomedicines. 2022 Dec 19;10(12):3294. doi: 10.3390/biomedicines10123294.